Quantum Leap Healthcare Collaborative
Quantum Leap Healthcare Collaborative reported $45.5 million in revenue and $62.6 million in expenses for calendar year 2024. Of every $100 it spent, $88.43 went to program services, $10.67 to management and general costs and $0.90 to fundraising. Its largest source of revenue was program service revenue such as fees, sales and contracts: 93.3% of the total. The highest compensation it reported for one person was $780,650 (CEO). 89 people received more than $100,000 in reportable compensation. Revenue rose 202% between 2019 and 2024. Source: Form 990, 2024.
Where $100 of spending went
Calendar year 2024 · Form 990, Part IX, line 25 · total expenses $63MFor context, the median across 3,614 covered human services charities: $88.27 programs, $11.52 management, $0.21 fundraising (medians computed separately, so they may not sum to $100).
Where $100 of revenue came from
Calendar year 2024 · Form 990, Part VIII · total revenue $46M- Contributions & grants (non-government)$1.93 $879K
- Program service revenue$93.16 $42M
- Investment income$4.91 $2.2M
Other revenue was negative: −$78,616. The bar shows the positive sources only.
The 990 scorecard · same measures for every charity, no grades
| Measure | 2024 | Median |
|---|---|---|
| Program services Part IX 25(B) ÷ 25(A) | 88.4% | 87.2% |
| Management & general Part IX 25(C) ÷ 25(A) | 10.7% | 11.4% |
| Fundraising Part IX 25(D) ÷ 25(A) | 0.9% | 0.2% |
| Fundraising cost per $1 of contributions Part IX 25(D) ÷ Part VIII 1h | $0.64 | $0.02 |
| Contributions & grants share of revenue Part VIII 1h ÷ 12 | 1.9% | 20.6% |
| Government grants share of revenue Part VIII 1e ÷ 12 | 0.0% | 2.4% |
| Program service revenue share Part VIII 2g ÷ 12 | 93.3% | 70.8% |
| Highest reported compensation Part VII-A, columns D–F | $780,650 | $274,992 |
| Highest compensation as share of expenses Part VII-A ÷ Part IX 25(A) | 1.25% | 1.18% |
| People paid over $100,000 Part VII, line 2 | 89 | 6 |
| Net assets, in months of expenses Part X 33(B) ÷ monthly expenses | 2.2 | 6.9 |
| Independent voting board members Part VI 1a–1b | 11 of 12 | 100.0% |
A median is context, not a target: hospitals, universities, food banks and grantmakers spend in very different ways. What these measures can and can't tell you.
What the money paid for, in its own words
2024 · Form 990, Part III · the three largest programs by expenseIspy 2.2 - I-spy 2.2 uses a 'sequential multiple assignment randomized trial' (smart) design - that is both smart and adaptive. The trial consists of up to three blocks of treatment. The first, block a, includes novel targeted therapies, without standard chemotherapy. If a patient achieves a complete response after block a, they can avoid toxic chemotherapy and go directly to surgery. If they have residual cancer, or the treatment is found to have little effect halfway through the course of treatment, they are recommended to proceed to treatment in block b. In block b, patients are assigned a…
Dcis - the re-evaluating conditions for active surveillance suitability as treatment: ductal carcinoma in situ (recast dcis) platform trial is a landmark phase 2 trial that is changing the lens through which we treat dcis. The study is aimed at preventing the progression of dcis to breast cancer and is evaluating three investigational endocrine therapy arms.with the objective to avoid over-treatment of low-risk dcis patients, this new trial offers dcis patients endocrine therapy with the intent to identify patients who are responsive to non-invasive treatment and have the option to omit…
Phase1b - pre I-spy is an open-label phase 1b platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-spy 2.2 trial and/or other oncology-based trials in a timely manner. The primary objectives of this platform trial are to determine the safety and tolerability of new agents/regimes in patients with certain advanced solid tumors and breast cancer while obtaining preliminary efficacy data of the new agents/regimes. The study was…
Highest reported compensation
2024 · Form 990, Part VII, Section A · roles as filed; names are in the filing, not here| Role | From this org | From related orgs | Other | Total |
|---|---|---|---|---|
| CEO Officer, 40.00 hrs/week | $705,144 | $0 | $75,506 | $780,650 |
| VICE PRESIDENT OF FINANCE Officer, 40.00 hrs/week | $471,944 | $0 | $50,100 | $522,044 |
| VICE PRES. STATISTICS (THRU 11/24) Key employee, 40.00 hrs/week | $489,716 | $0 | $30,107 | $519,823 |
| SR. VP, CLINICAL OPS & COMPLIANCE Key employee, 40.00 hrs/week | $344,211 | $0 | $57,369 | $401,580 |
| DIRECTOR OF BIOMETRICS, ONCOLOGY Highest compensated employee, 40.00 hrs/week | $317,177 | $0 | $62,825 | $380,002 |
| DIRECTOR OF I-SPY COVID TRIAL Highest compensated employee, 40.00 hrs/week | $292,216 | $0 | $49,851 | $342,067 |
| VP QUALITY ASSURANCE Key employee, 40.00 hrs/week | $276,863 | $0 | $56,317 | $333,180 |
| CHIEF COLLABORATION OFFICER Highest compensated employee, 40.00 hrs/week | $280,507 | $0 | $46,971 | $327,478 |
89 people received more than $100,000 in reportable compensation from Quantum Leap Healthcare Collaborative (Part VII, line 2). Compensation of current officers, directors and key employees totaled $3.1M (Part IX, line 5).
6 years of filings
Form 990, Parts I, VII, IX and X · each row is that year's own filing, linkedGovernance answers, as filed
2024 · the organization's own yes/no answers; explanations, if any, are in Schedule O of the filing · what each means- Voting board members, and how many are independent Part VI, lines 1a–1b12 · 11 independent
- Audited financial statements Part XII 2bYes
- Conflict-of-interest policy Part VI 12aYes
- Whistleblower policy Part VI 13Yes
- Document retention policy Part VI 14Yes
- Independent process for top executive pay Part VI 15aYes
- Board given the 990 before filing Part VI 11aYes
- Family or business ties among insiders Part VI 2No
- Aware of a significant diversion of assets Part VI 5No
- Excess benefit transaction with an insider Part IV 25aNo
- Loans to or from insiders outstanding Part IV 26No
- Lobbying, or a 501(h) election in effect Part IV 4No
- Over $15,000 of professional fundraising services Part IV 18No
- Over $10,000 of activity outside the U.S. Part IV 14bNo
- Employees Part I, line 5114
- Volunteers Part I, line 615
Largest outside contractors
2024 · Form 990, Part VII, Section B · businesses only| REGENTS OF UC SAN FRANCISCO Clinical research | $7,394,491 |
| UNIVERSITY OF CALIFORNIA SAN DIEGO Cell-free dna tests | $1,651,000 |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM - CO Clinical research | $1,313,529 |
| NATERA INC Clinical research | $1,313,529 |
| YOURWAY TRANSPORT INC Clinical packager & premium courier | $1,201,250 |
Individuals listed as contractors are left out. 61 contractors were paid more than $100,000 in all.
Private foundation grants it received
1 private foundation reported grants to Quantum Leap Healthcare Collaborative totaling $75,000 on their tax year 2023 Form 990-PF returns. See which foundations, on WHOFUNDS.
Source: WHOFUNDS open grant graph, matched from Form 990-PF Part XV.
Correct a figure or respond
Every number above is copied from Quantum Leap Healthcare Collaborative's own Form 990. If one doesn't match the filing, that's our error and we'll fix it. If you work for Quantum Leap Healthcare Collaborative, you can publish a response that is linked from this page.
Share or embed this breakdown
Of every $100 Quantum Leap Healthcare Collaborative spent in 2024, $88.43 went to programs. The full breakdown, from its IRS Form 990:
Embed on your site
Similar-sized charities in this cause
- The Children's Home of Cincinnati OhioCincinnati, OH · revenue $46M · programs 87.0% · FY2025
- ForestdaleForest Hills, NY · revenue $46M · programs 86.8% · FY2025
- Goodwill Industries of Ventura and Santa Barbara CountiesOxnard, CA · revenue $45M · programs 83.7% · 2024
- Florence Crittenton Services of Orance CountyFullerton, CA · revenue $46M · programs 88.7% · FY2025
- Nysarc Inc. Rockland County ChapterValley Cottage, NY · revenue $45M · programs 89.4% · 2024
All human services charities · Largest charities in California
Questions people ask
How much of Quantum Leap Healthcare Collaborative's spending goes to programs?
In calendar year 2024, Quantum Leap Healthcare Collaborative reported that 88.4% of its $62.6 million in expenses went to program services, 10.7% to management and general and 0.9% to fundraising (Form 990, Part IX).
How much does Quantum Leap Healthcare Collaborative pay its top executive?
The largest total compensation Quantum Leap Healthcare Collaborative reported for one person in calendar year 2024 was $780,650, for the role of CEO (Form 990, Part VII, including compensation from related organizations and other compensation).
Where does Quantum Leap Healthcare Collaborative get its money?
Of $45.5 million in revenue in calendar year 2024, 1.9% came from contributions and grants and 93.3% from program service revenue (Form 990, Part VIII).
Is Quantum Leap Healthcare Collaborative a registered charity?
The IRS lists EIN 20-4284925 as a 501(c)(3) organization (publicly supported organization (170(b)(1)(a)(vi))), and its records show contributions as tax-deductible. Form 990 filings on record here cover tax years 2019, 2020, 2021, 2022, 2023, 2024. A filing shows what the organization reported; it doesn't by itself show whether a program works.
Sources
- 2024: Form 990 for calendar year 2024, object 202543219349320879 · read the filing · XML
- 2023: Form 990 for calendar year 2023, object 202443179349303079 · read the filing
- 2022: Form 990 for calendar year 2022, object 202303199349309725 · read the filing
- 2021: Form 990 for calendar year 2021 (amended), object 202331779349301358 · read the filing
- 2020: Form 990 for calendar year 2020, object 202123199349327477 · read the filing
- 2019: Form 990 for calendar year 2019, object 202013169349305526 · read the filing
All filings for EIN 20-4284925: ProPublica Nonprofit Explorer · IRS Tax Exempt Organization Search. Figures are as the organization reported them; we have not audited them.